InvestSMART

Atomos Limited (ASX:AMS)

ALERT: Price-sensitive ASX Announcement for AMS
Current share price for AMS : $0.012 0.002 (20%)+
Announcement
Release
31 Jul 2026 7:05PM
Price at Release
$0.010
Full Release
download
Summary
Atomos Limited's Q4 FY26 report highlights significant events including the closure of new finance facilities and the completion of the Flanders Scientific acquisition. Despite lower than anticipated cash receipts due to timing issues, Atomos managed to launch several products and maintain a strategic focus on expanding their ecosystem. The company secured a $10 million facility with CBA and achieved a repricing of the Monreii Facility, leading to annual interest savings. Ending the quarter with $2.3 million in cash, Atomos is optimistic about sustaining sales growth and profitability into FY27.
Key Points
  • Atomos Limited reported Q4 FY26 cash receipts of $6.1 million, lower than anticipated.
  • Product manufacturing and operating costs in Q4 FY26 amounted to $7.8 million, including several one-off expenses.
  • Net operating cash outflow for Q4 FY26 was $5.7 million.
  • The acquisition of Flanders Scientific was completed in April 2026.
  • A $10 million finance facility was established with Commonwealth Bank in April 2026.
  • Concurrent repricing of Monreii Facility from 20% to 13% per annum was achieved.
  • Atomos launched several new products, including Shogun AV-19 and Sumo PRO 19.
  • Atomos ended Q4 FY26 with $2.3 million in cash and cash equivalents.
  • Net cash from financing activities in Q4 FY26 was $8.9 million.
  • The company anticipates sales growth and EBITDA profitability in FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.